Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (12): 1308-1313.doi: 10.3969/j.issn.1000-6621.2021.12.014
• Original Articles • Previous Articles Next Articles
WU Bi-tong, CAI Xing-shan, KUANG Hao-bin, LIU Zhi-hui, MENG Fan-rong, WANG Nan, GAO Jun-wen, TAN Shou-yong()
Received:
2021-06-28
Online:
2021-12-10
Published:
2021-12-01
Contact:
TAN Shou-yong
E-mail:tanshouyong@163.com
WU Bi-tong, CAI Xing-shan, KUANG Hao-bin, LIU Zhi-hui, MENG Fan-rong, WANG Nan, GAO Jun-wen, TAN Shou-yong. Correlation between pyrazinamidase activity and the short-term clinical efficacy of multidrug-resistant pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1308-1313. doi: 10.3969/j.issn.1000-6621.2021.12.014
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.12.014
特征 | 吡嗪酰胺酶阳性(32例) | 吡嗪酰胺酶阴性(44例) | 检验值 | P值 |
---|---|---|---|---|
年龄(岁, | 40.6±10.4 | 41.4±10.6 | t=0.312 | 0.763 |
性别[例(构成比,%)] | χ2=0.441 | 0.507 | ||
男性 | 22(68.8) | 27(61.4) | ||
女性 | 10(31.2) | 17(38.6) | ||
治疗分类[例(构成比,%)] | χ2=0.105 | 0.746 | ||
初治 | 6(18.8) | 7(15.9) | ||
复治 | 26(81.2) | 37(84.1) | ||
病灶位置[例(构成比,%)] | χ2=0.215 | 0.643 | ||
单侧 | 10(31.2) | 16(36.4) | ||
双侧 | 22(68.8) | 28(63.6) | ||
并发空洞[例(发生率,%)] | 29(90.6) | 38(86.4) | χ2=0.322 | 0.570 |
吡嗪酰胺表型药敏[例(构成比,%)] | Kappa=0.687a | 0.000 | ||
敏感 | 30(93.8) | 10(22.7) | ||
耐药 | 2(6.2) | 34(77.3) |
[1] |
Huy NQ, Lucie C, Hoa TTT, et al. Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates. Emerg Microbes Infect, 2017, 6(10):e86. doi: 10.1038/emi.2017.73.
doi: 10.1038/emi.2017.73 |
[2] |
Hoffner S, Angeby K, Sturegård E, et al. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. Int J Tuberc Lung Dis, 2013, 17(11):1486-1490. doi: 10.5588/ijtld.13.0195.
doi: 10.5588/ijtld.13.0195 pmid: 24125455 |
[3] |
Daum LT, Konstantynovska OS, Solodiankin OS, et al. Characterization of novel Mycobacterium tuberculosis pncA gene mutations in clinical isolates from the Ukraine. Diagn Microbiol Infect Dis, 2019, 93(4):334-338. doi: 10.1016/j.diagmicrobio.2018.10.018.
doi: 10.1016/j.diagmicrobio.2018.10.018 URL |
[4] |
Ramirez-Busby SM, Rodwell TC, Fink L, et al. A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. Sci Rep, 2017, 7(1):3790. doi: 10.1038/s41598-017-03452-y.
doi: 10.1038/s41598-017-03452-y pmid: 28630430 |
[5] | World Health Organization. WHO treatment guideline for drug-resistant tuberculosis (2016 update). Geneva: World Health Organization, 2016. |
[6] |
Njire M, Tan Y, Mugweru J, et al. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Adv Med Sci, 2016, 61(1):63-71. doi: 10.1016/j.advms.2015.09.007.
doi: 10.1016/j.advms.2015.09.007 URL |
[7] |
Iacobino A, Piccaro G, Giannoni F, et al. Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli. Int J Mycobacteriol, 2017, 6(3):213-221. doi: 10.4103/ijmy.ijmy_85_17.
doi: 10.4103/ijmy.ijmy_85_17 pmid: 28776518 |
[8] |
Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science, 2011, 333(6049):1630-1632. doi: 10.1126/science.1208813.
doi: 10.1126/science.1208813 URL |
[9] |
Khan MT, Khan A, Rehman AU, et al. Structural and free energy landscape of novel mutations in ribosomal protein S1 (rpsA) associated with pyrazinamide resistance. Sci Rep, 2019, 9(1):7482. doi: 10.1038/s41598-019-44013-9.
doi: 10.1038/s41598-019-44013-9 URL |
[10] |
Bouzouita I, Cabibbe AM, Trovato A, et al. Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance? Int J Tuberc Lung Dis, 2018, 22(6):661-666. doi: 10.5588/ijtld.17.0715.
doi: 10.5588/ijtld.17.0715 pmid: 29862951 |
[11] |
车洋, 杨天池, 林相, 等. 浙江省宁波市耐多药结核分枝杆菌吡嗪酰胺耐药特征及与二线抗结核药物耐药关系. 疾病监测, 2020, 35(3):237-241. doi: 10.3784/j.issn.1003-9961.2020.03.013.
doi: 10.3784/j.issn.1003-9961.2020.03.013 |
[12] |
Yee DP, Menzies D, Brassard P. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. Int J Tuberc Lung Dis, 2012, 16(5):604-609. doi: 10.5588/ijtld.11.0376.
doi: 10.5588/ijtld.11.0376 pmid: 22409887 |
[13] |
吴碧彤, 邝浩斌, 刘志辉, 等. 标准耐多药结核病化疗方案中是否对吡嗪酰胺耐药的疗效对比研究. 中国防痨杂志, 2019, 41(4):447-451. doi: 10.3969/j.issn.1000-6621.2019.04.015.
doi: 10.3969/j.issn.1000-6621.2019.04.015 |
[14] |
Njire M, Tan Y, Mugweru J, et al. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Adv Med Sci, 2016, 61(1):63-71. doi: 10.1016/j.advms.2015.09.007.
doi: 10.1016/j.advms.2015.09.007 URL |
[15] |
Gupta UD, Vemuri N, Gupta P, et al. Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model. Indian J Med Res, 2015, 142(3):323-329. doi: 10.4103/0971-5916.166599.
doi: 10.4103/0971-5916.166599 pmid: 26458349 |
[16] |
Sun F, Li Y, Chen Y, et al. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study. Eur Respir J, 2019, 53(3):1801770. doi: 10.1183/13993003.01770-2018.
doi: 10.1183/13993003.01770-2018 URL |
[17] |
关平. 广东地区结核分枝杆菌吡嗪酰胺耐药的pncA、rpsA、panD基因分型特征研究. 国际检验医学杂志, 2019, 40(17):2066-2069. doi: 10.3969/j.issn.1673-4130.2019.17.004.
doi: 10.3969/j.issn.1673-4130.2019.17.004 |
[18] |
Werngren J, Alm E, Mansjö M. Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That? J Clin Microbiol, 2017, 55(6):1920-1927. doi: 10.1128/JCM.02532-16.
doi: 10.1128/JCM.02532-16 pmid: 28404681 |
[19] |
洪创跃, 杨婷婷, 李金莉, 等. 深圳市耐多药结核分枝杆菌耐药基因突变特征分析. 中国防痨杂志, 2020, 42(6):583-589. doi: 10.3969/j.issn.1000-6621.2020.06.009.
doi: 10.3969/j.issn.1000-6621.2020.06.009 |
[1] | HU Yan-jie, GONG Shi-wei, REN Yi. Establishment and evaluation of rapid detection of pyrazinamide resistance of Mycobacterium tuberculosis by probe enzyme digestion using Surveyor [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 813-816. |
[2] | QIN Yao, CAI Qing-shan, BAO Zhi-jian. Analysis of clinical characteristics and prognosis of 21 pregnant women complicated with tuberculosis after in vitro fertilization-embryo transfer [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 682-688. |
[3] | XUE Hai-bin, LUO Xiao-bo, SUN Fei, JIAN Wei, LI Jin-long. Analysis of clinical efficacy of posterior transforaminal debridement and interbody fusion with instrumentation via tubular retractor system for lumbar tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 457-462. |
[4] | Maiweilanjiang· Abulimiti, Diermulati· Tusun, LIU Zhen-jiang, Xirizhati· Mamuti, LI Guan-zhen, OU Xi-chao. Analysis on the therapeutic effect and influencing factors of initial treated smear-positive pulmonary tuberculosis patients in Kashgar Prefecture from 2016 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 391-397. |
[5] | YANG Ni, SU Qian, XIAO Yue, LU Jia, SONG Yang, RAO Zheng-yuan, XIA Lan, HE Jin-ge, CHEN Chuang, ZHANG Ling-lin. Analysis on treatment outcomes and influencing factors of 2158 patients with MTB/HIV co-infection [J]. Chinese Journal of Antituberculosis, 2021, 43(3): 274-279. |
[6] | ZHAO Yong, LIN Shu-fang, LIN Jian, DAI Zhi-song, WEI Shu-zhen. Analysis of pyrazinamide resistance and pncA mutation in 125 multidrug-resistant Mycobacterium tuberculosis isolates [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1079-1083. |
[7] | DUAN Li-ming, DING Chao, LIU Yu-gang, WEI Lin, GU Zhen-ning. Application value of video-assisted thoracoscopic surgery in the treatment of chronic tuberculous empyema [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 850-853. |
[8] | LIU Lin. Clinical analysis of 35 pregnant tuberculous pleurisy patients [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 731-736. |
[9] | BAO Rui, LIU Xiao-yang, REN Peng, ZHANG Feng, LIANG Hai-yan, WANG Ru, FU Ling, GAN Di-shou. Analysis of surgical treatment characteristics in patients with spinal tuberculosis and HIV co-infection [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 645-648. |
[10] | HE Min, PU Yu, CAI Yu-guo, LI Bang-yin, HE Lei, HUAN Ming-cang. Observation on the clinical effect of surgical treatment for 23 patients with spinal tuberculosis complicated with AIDS [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 454-458. |
[11] | BIN Song-tao, WANG Ji, TAN Li, WU Cheng-qing, WANG Yan-chun, LI Ming. Observation on the effects of bronchoscopy diagnosis and interventional treatment in 11 children with tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 523-526. |
[12] | KANG Yi,FU Man-jiao. Clinical analysis of 11 patients with severe tuberculosis in pregnancy or puerperium [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 385-390. |
[13] | JIAN Yi-luan,WU Long-zhang,GU Zhuo-yun. Clinical characteristics and treatment outcomes of 18 patients with non-tuberculosis mycobacteria concerning eyes, ears, nose and throat [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 255-258. |
[14] | LI Zhi-ming,YU Shan,WANG Tao.. Clinical effect analysis of Chaizhushigao Decoction in 29 recurrent fever tuberculosis patients complicated with other infections [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 121-125. |
[15] | CHEN Pin-ru,TAN Shou-yong. The role of surgery in the treatment of non-tuberculous mycobacterium pulmonary disease [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 159-163. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||